Suppr超能文献

VP - 16类似物的构效关系。

Structure-activity relationships of VP-16 analogues.

作者信息

Long B H, Casazza A M

机构信息

Experimental Therapeutics, Oncology Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000.

出版信息

Cancer Chemother Pharmacol. 1994;34 Suppl:S26-31. doi: 10.1007/BF00684860.

Abstract

A total of 27 selected analogues of VP-16 and VM-26 were compared with VP-16 and VM-26 for their relative abilities to stabilize the enzyme-substrate intermediate normally formed between eukaryote topoisomerase II and DNA. This activity was compared with cytotoxicity results obtained using the human colon HCT116 cell line and antitumor results obtained after intraperitoneal injection of mice with murine leukemia P388. The most potent analogues were those containing OH groups (demethyl) in either the 3' and 4' or the 3', 4', and 5' positions, the latter being twice as potent as VP-16. VM-26 was only 40% more potent than VP-16 in this assay. It was generally found that the 4'-esters had little activity in vitro, yet were cytotoxic and had antitumor activities. All other analogues with little in vitro activity were not very cytotoxic and had little if any antitumor activity. A very good correlation exists between stabilization of topoisomerase II-DNA intermediates, cytotoxicity, and antitumor activity.

摘要

总共27种选定的依托泊苷(VP - 16)和替尼泊苷(VM - 26)类似物与VP - 16和VM - 26进行了比较,以评估它们稳定真核生物拓扑异构酶II与DNA之间正常形成的酶 - 底物中间体的相对能力。将该活性与使用人结肠HCT116细胞系获得的细胞毒性结果以及给小鼠腹腔注射鼠白血病P388后获得的抗肿瘤结果进行了比较。最有效的类似物是那些在3'和4'或3'、4'和5'位含有羟基(去甲基)的类似物,后者的效力是VP - 16的两倍。在该测定中,VM - 26仅比VP - 16效力高40%。一般发现,4'-酯在体外几乎没有活性,但具有细胞毒性和抗肿瘤活性。所有其他体外活性很小的类似物细胞毒性也很小,几乎没有或没有抗肿瘤活性。拓扑异构酶II - DNA中间体的稳定、细胞毒性和抗肿瘤活性之间存在非常好的相关性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验